SU
Supriya Lifescience Ltd (SUPRIYA)
₹847.30
Mkt cap
₹6,819 Cr
P/E ratio
34.30
P/B
5.69
Div yield
0.12%
ROE
19.10%
ROCE
25.20%
EPS (TTM)
₹24.70
Book value
₹149
52W range
546–1,085
Sector
Healthcare
Price history
Previous close
Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. [1]
NSE SUPRIYABSE 543434
Health check
Constructive
ValuationFair
ProfitabilityStrong
GrowthHigh
TechnicalsNeutral
52-week range
−21.91% from high₹847
₹546+55.33% from low₹1,085
Current
₹847.30
Prev close
₹869.30
Day
−2.53%
Price performance
1D
−1.07%
1W
+5.06%
1M
−12.69%
3M
+0.01%
6M
+23.17%
1Y
+15.52%
YTD
+12.89%
Financials
Revenue, profit & margin
P/E ratio
34.3×
SUPRIYA is 0% below the sector median of 34.4×
SUPRIYA34.3×
Sector median34.4×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 132 | 140 | 140 | 158 | 161 | 166 | 186 | 184 | 145 | 200 | 206 | 277 | 190 | |
| Expenses | 88 | 108 | 99 | 103 | 98 | 101 | 120 | 117 | 93 | 127 | 134 | 179 | 142 | |
| Operating Profit | 44 | 32 | 41 | 56 | 63 | 65 | 66 | 68 | 52 | 73 | 72 | 98 | 47 | |
| OPM % | 34% | 23% | 30% | 35% | 39% | 39% | 36% | 37% | 36% | 36% | 35% | 35% | 25% | |
| Other Income | 3 | 2 | 3 | 2 | 2 | 3 | 2 | 3 | 3 | 3 | 2 | 3 | 3 | |
| Interest | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | |
| Depreciation | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 6 | 6 | 7 | 7 | 8 | 9 | |
| Profit before tax | 43 | 30 | 40 | 53 | 60 | 62 | 63 | 64 | 47 | 68 | 67 | 92 | 41 | |
| Tax % | 33% | 20% | 26% | 31% | 25% | 26% | 25% | 21% | 27% | 26% | 26% | 19% | 41% | |
| Net Profit | 29 | 24 | 30 | 37 | 45 | 46 | 47 | 50 | 35 | 50 | 50 | 74 | 24 | |
| EPS in Rs | 3.54 | 2.97 | 3.70 | 4.59 | 5.55 | 5.73 | 5.81 | 6.26 | 4.32 | 6.27 | 6.17 | 9.22 | 2.99 | |
| Raw PDF |
Earnings
Results dates & reactionsNext results
6 Nov '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −2.69% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 13 Aug '26◦ |
| Earnings day | −2.69% |
| +1 day | −3.63% |
| +5 days | −0.99% |
| +15 days | +4.84% |
| +30 days | +21.05% |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Sep 202668.30%Promoter
Promoters68.30%
FIIs6.45%0.27
DIIs5.47%0.17
Public19.80%0.41
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Supriya Lifesci. | ₹847.30 | 34.32 | 6,819 | 0.12% | 24 | −30.90% | 190 | +30.80% | 25.17% |
| Median: 158 Co. | ₹426.38 | 34.39 | 1,921 | 0.08% | 14 | +22.08% | 175 | +18.92% | 15.12% |
Filings
Annual reports6
Concall transcripts51
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025RECAug 2025TranscriptMay 2025PPTMay 2025RECMay 2025TranscriptJan 2025PPTJan 2025RECJan 2025TranscriptNov 2024PPTNov 2024RECNov 2024TranscriptAug 2024
Credit ratings6
Announcements5
Board Meeting Intimation for Quarter And Half Year Ended September 30, 2026 30 Oct - Board meets on November 6, 2026 to approve Q2 and half-year unaudited financial results.Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015. 19 Oct - Supreme Court admitted the case and stayed coercive action against directors/officers pending hearing.Announcement On ESG Ratings 13 Oct - CRISIL ESG Ratings assigned Supriya Lifescience a ‘CRISIL ESG 65’ score in the ‘Strong’ category.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 12 Oct - Regulation 74(5) compliance certificate for quarter ended September 30, 2026.Announcement Under Regulation 30 Of SEBI(LODR) Regulations, 2015. 8 Oct - Supriya Lifescience filed a Supreme Court petition on October 8, 2026 regarding ongoing judicial proceedings.